Rhythm Pharmaceuticals develops and sells IMCIVREE, a treatment for rare genetic forms of obesity. It last closed at $116.61 on Nov 17, up 8.49% on the day. The average 12-month price target from 8 analysts is $138.88 (+19.1% from the last close), with a high of $166.00 and a low of $114.00. Analyst consensus is Strong Buy, based on the latest ratings from 8 firms (7 buy, 1 hold, 0 sell). In the past 30 days there were 5 dark pool prints totaling $4.3M, the largest $1.3M.
Each firm's latest rating on RYTM in the past 90 days
Average 12-month target
$138.88
▲ 19.1% upside
Based on 8 analysts who set a price target on RYTM in the past 90 days. The average target is $138.88, with a high of $166.00 and a low of $114.00, compared with the last close of $116.61.
Low $114.00Avg $138.88High $166.00
Blue marker: last close $116.61
Highest target$166.00
Average target$138.88
Lowest target$114.00
Latest rating changes
JP MorganTarget lowered
Nov 7Buy$146 → $142
GuggenheimMaintained
Nov 5Buy$147
CitizensTarget raised
Nov 4Buy$160 → $166
NeedhamMaintained
Nov 3Buy$114
HC Wainwright & Co.Maintained
Oct 12Buy$130
Date
Firm
Action
Rating
Price target
Nov 7
JP Morgan
Target lowered
Buy
$146 → $142
Nov 5
Guggenheim
Maintained
Buy
$147
Nov 4
Citizens
Target raised
Buy
$160 → $166
Nov 3
Needham
Maintained
Buy
$114
Oct 12
HC Wainwright & Co.
Maintained
Buy
$130
Loading…
Technical Analysis
RYTM · as of the Nov 17 close · updated after every close
Uptrend, nearing overbought
The stock is 13% above its 20 day and 17% above its 50 day average. It is 17% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 64), near overbought. The nearest support is the Pivot at $113.10, and the nearest resistance the swing high (Aug 19) at $118.31.
Short trendBullish
Long trendBullish
MomentumStrong
StretchNear overbought
VolatilityHigh, 5.4%/day
Key levels
$122.2052 week high+4.8%
$122.01Pivot R1+4.6%
$118.31Swing high (Aug 19)+1.5%
$116.61Last close
$113.10Pivot−3.0%
$111.42Swing low (Aug 12)−4.5%
$107.70Pivot S1−7.6%
$103.31100 day average−11.4%
$101.2520 day average−13.2%
$97.31200 day average−16.6%
$97.2750 day average−16.6%
$74.5052 week low−36.1%
Indicators
RSI (14)
63.50
Strong, overbought above 70
Neutral
MACD
5.47
Above its signal line
Bullish
Stochastic
86.2
Near the top of its range
Overbought
ADX (14)
29.7
Trending up
Williams %R
-5.1
Oversold below −80, overbought above −20
Overbought
CCI (20)
83.6
Oversold below −100, overbought above 100
Neutral
Rate of change
+34.9%
Change over 10 sessions
Bullish
ATR (14)
$6.26
Typical daily range, 5.4% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200Above
Rising, nearing overbought
Short trendBullish
Long trendNot enough history
MomentumStrong
StretchNear overbought
VolatilityNormal, 9.0%/day
Key levels
$122.2052 week high+4.8%
$122.01Pivot R1+4.6%
$118.31Swing high (Aug 19)+1.5%
$116.61Last close
$113.10Pivot−3.0%
$111.42Swing low (Aug 12)−4.5%
$107.70Pivot S1−7.6%
$103.31100 day average−11.4%
$101.2520 day average−13.2%
$97.31200 day average−16.6%
$97.2750 day average−16.6%
$74.5052 week low−36.1%
Indicators
RSI (14)
62.25
Strong, overbought above 70
Neutral
MACD
2.32
Above its signal line
Bullish
Stochastic
87.6
Near the top of its range
Overbought
ADX (14)
17.8
No clear trend
Williams %R
-5.1
Oversold below −80, overbought above −20
Overbought
CCI (20)
96.9
Oversold below −100, overbought above 100
Neutral
Rate of change
+11.4%
Change over 10 sessions
Bullish
ATR (14)
$10.47
Typical daily range, 9.0% of price
MA 10Above
MA 20Above
MA 50Above
MA 100Above
MA 200–
What happened before, for RYTM
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
Signal name goes hereSince a recent date
9 times
+0.0%
What happened before
See how RYTM did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
November seasonalityHow RYTM usually does this month. See Seasonality
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How RYTM has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2017.
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper trading
StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether RYTM is in one of them and how their past RYTM trades turned out.
Rhythm Pharmaceuticals is a biopharmaceutical company based in Boston, Massachusetts, in the United States. It sells IMCIVREE, a treatment that acts on the MC4R pathway in the brain, for patients with certain rare genetic forms of obesity, such as Bardet Biedl syndrome. The company is also developing other MC4R agonist treatments for hypothalamic obesity and other rare conditions. Its customers are patients with these rare diseases, along with the physicians and healthcare providers who treat them.